258 related articles for article (PubMed ID: 27602589)
1. Identification of dual ligands targeting angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ by core hopping of telmisartan.
Zhang J; Liu X; Wang SQ; Liu GY; Xu WR; Cheng XC; Wang RL
J Biomol Struct Dyn; 2017 Sep; 35(12):2665-2680. PubMed ID: 27602589
[TBL] [Abstract][Full Text] [Related]
2. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.
Walcher D; Hess K; Heinz P; Petscher K; Vasic D; Kintscher U; Clemenz M; Hartge M; Raps K; Hombach V; Marx N
Hypertension; 2008 Feb; 51(2):259-66. PubMed ID: 18158351
[TBL] [Abstract][Full Text] [Related]
4. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
[TBL] [Abstract][Full Text] [Related]
5. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
[TBL] [Abstract][Full Text] [Related]
6. Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.
Zhang J; Hao QQ; Liu X; Jing Z; Jia WQ; Wang SQ; Xu WR; Cheng XC; Wang RL
Oncotarget; 2017 Apr; 8(15):25612-25627. PubMed ID: 28445965
[TBL] [Abstract][Full Text] [Related]
7. AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ.
Tiyerili V; Becher UM; Aksoy A; Lütjohann D; Wassmann S; Nickenig G; Mueller CF
Cardiovasc Diabetol; 2013 Feb; 12():30. PubMed ID: 23374104
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
9. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.
Mizuno CS; Chittiboyina AG; Shah FH; Patny A; Kurtz TW; Pershadsingh HA; Speth RC; Karamyan VT; Carvalho PB; Avery MA
J Med Chem; 2010 Feb; 53(3):1076-85. PubMed ID: 20073471
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes.
Furukawa H; Mawatari K; Koyama K; Yasui S; Morizumi R; Shimohata T; Harada N; Takahashi A; Nakaya Y
Eur J Pharmacol; 2011 Jun; 660(2-3):485-91. PubMed ID: 21514293
[TBL] [Abstract][Full Text] [Related]
12. Beyond the classic angiotensin-receptor-blocker profile.
Kurtz TW
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S19-26. PubMed ID: 18580862
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.
Hu ZP; Fang XL; Qian HY; Fang N; Wang BN; Wang Y
Fundam Clin Pharmacol; 2014 Oct; 28(5):501-11. PubMed ID: 24188213
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for telmisartan-mediated partial activation of PPAR gamma.
Amano Y; Yamaguchi T; Ohno K; Niimi T; Orita M; Sakashita H; Takeuchi M
Hypertens Res; 2012 Jul; 35(7):715-9. PubMed ID: 22357520
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
[TBL] [Abstract][Full Text] [Related]
16. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
[TBL] [Abstract][Full Text] [Related]
17. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice.
Fukuda D; Enomoto S; Hirata Y; Nagai R; Sata M
Biomed Pharmacother; 2010 Dec; 64(10):712-7. PubMed ID: 20970951
[TBL] [Abstract][Full Text] [Related]
18. Neurorestoration after traumatic brain injury through angiotensin II receptor blockage.
Villapol S; Balarezo MG; Affram K; Saavedra JM; Symes AJ
Brain; 2015 Nov; 138(Pt 11):3299-315. PubMed ID: 26115674
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
Nakano A; Hattori Y; Aoki C; Jojima T; Kasai K
Hypertens Res; 2009 Sep; 32(9):765-9. PubMed ID: 19590508
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M
Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
